KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gross Profit (2016 - 2025)

Regeneron Pharmaceuticals has reported Gross Profit over the past 17 years, most recently at $3.6 billion for Q4 2025.

  • Quarterly results put Gross Profit at $3.6 billion for Q4 2025, up 2.98% from a year ago — trailing twelve months through Dec 2025 was $13.3 billion (up 0.86% YoY), and the annual figure for FY2025 was $13.2 billion, up 0.67%.
  • Gross Profit for Q4 2025 was $3.6 billion at Regeneron Pharmaceuticals, up from $3.5 billion in the prior quarter.
  • Over the last five years, Gross Profit for REGN hit a ceiling of $5.0 billion in Q2 2021 and a floor of -$237.2 million in Q4 2022.
  • Median Gross Profit over the past 5 years was $3.0 billion (2023), compared with a mean of $2.7 billion.
  • Biggest five-year swings in Gross Profit: tumbled 366.01% in 2022 and later soared 1951.88% in 2023.
  • Regeneron Pharmaceuticals' Gross Profit stood at -$50.9 million in 2021, then tumbled by 366.01% to -$237.2 million in 2022, then skyrocketed by 1418.51% to $3.1 billion in 2023, then increased by 10.71% to $3.5 billion in 2024, then grew by 2.98% to $3.6 billion in 2025.
  • The last three reported values for Gross Profit were $3.6 billion (Q4 2025), $3.5 billion (Q3 2025), and $3.4 billion (Q2 2025) per Business Quant data.